QureTech Bio partner in Swedish Research Council-funded project

December 15, 2025

QureTech Bio AB (“QureTech”) today announced its participation as a collaborative partner in the research project “Enabling future cancer treatments – Developing new antibiotics targeting hard-to-treat bacteria”. The project is led by Professor Jörgen Johansson at Umeå University with Professor Fredrik Almqvist as a co-applicant.

The project has been awarded SEK 3.45 million by the Swedish Research Council under the call “Project grant for cross-sectoral collaboration within medicine and health 2025”. The research project aims to develop novel antibiotics targeting hard-to-treat bacteria, an important step in enabling more effective cancer therapies where infections from resistant bacteria often limit treatment options and outcomes.

“Without effective antibiotics, many cancer treatments would be very dangerous or impossible to carry out due to the risk of infection. Together with QureTech, we are studying compounds that can rapidly kill bacteria in biofilms and persister cells, with the goal of enabling safer and more effective cancer treatments,” says Jörgen Johansson, Professor at Umeå University.

“Being a partner in this project is fully aligned with our mission to advance therapies that make a real difference for patients facing complex diseases like cancer,” said Markus Thor, CEO of QureTech.

Contact
Markus Thor, CEO
E-mail: markus.thor@quretech.com
Telephone: +46 70 644 99 91
Web: www.quretech.com

About QureTech Bio

QureTech Bio AB is a biotechnology company developing new solutions to combat disease-causing bacteria to tackle one of our times’ greatest health threats, antimicrobial resistance (AMR). The company’s lead program is focused on developing a new class of antibiotics, called GmPcides, that are effective against multidrug resistant Gram-positive bacteria. QureTech is located in Umeå, Sweden.

QureTech Bio partner in Swedish Research Council-funded project